An open-label extension study to evaluate the long-term safety and tolerability of Lu AE58054 as adjunctive treatment to donepezil in patients with mild-moderate Alzheimer's disease

M
Martin Farlow, MD

Primary Investigator

J
Jessica MacLean

Primary Investigator

Overview

This study is designed as a classic open-label extension study with add-on design to evaluate the long-term safety and tolerability of Lu AE8054 as adjunctive therapy to donepezil in subjects with mild-moderate Alzheimer?s disease (AD).

Description

This study is designed as a classic open-label extension study with add-on design to evaluate the long-term safety and tolerability of Lu AE8054 as adjunctive therapy to donepezil in subjects with mild-moderate Alzheimer?s disease (AD).

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Alzheimer's disease
  • Age: - 100 Years
  • Gender: All
Updated on 20 Nov 2022. Study ID: 1404753701

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center